Androgen deprivation therapy and cardiovascular morbidity in prostate cancer : a narrative review
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Prostate cancer is the most common malignancy in men, mostly affecting older men who harbor an increased prevalence of cardiovascular disease and metabolic syndrome. Androgen deprivation therapy (ADT), the standard therapy for various stages of prostate cancer, further increases the risk for cardiovascular disease and for metabolic syndrome. Therefore, screening for cardiovascular risk factors should be performed prior to the initiation of ADT, and, if necessary, cardiological evaluation and interdisciplinary management should be provided during and after completion of ADT. Moreover, the use of a gonadotropin-releasing hormone (GnRH) antagonist may help reduce cardiovascular risk in patients with cardiovascular disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Urologie (Heidelberg, Germany) - 63(2024), 3 vom: 27. März, Seite 262-268 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review |
|---|
| Beteiligte Personen: |
Klemm, Jakob [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.03.2024 Date Revised 07.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00120-023-02222-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363666168 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363666168 | ||
| 003 | DE-627 | ||
| 005 | 20240307232031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00120-023-02222-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM363666168 | ||
| 035 | |a (NLM)37874334 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Klemm, Jakob |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Androgen deprivation therapy and cardiovascular morbidity in prostate cancer |b a narrative review |
| 246 | 3 | 3 | |a Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Prostate cancer is the most common malignancy in men, mostly affecting older men who harbor an increased prevalence of cardiovascular disease and metabolic syndrome. Androgen deprivation therapy (ADT), the standard therapy for various stages of prostate cancer, further increases the risk for cardiovascular disease and for metabolic syndrome. Therefore, screening for cardiovascular risk factors should be performed prior to the initiation of ADT, and, if necessary, cardiological evaluation and interdisciplinary management should be provided during and after completion of ADT. Moreover, the use of a gonadotropin-releasing hormone (GnRH) antagonist may help reduce cardiovascular risk in patients with cardiovascular disease | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Androgen deprivation therapy | |
| 650 | 4 | |a Cardiovascular morbidity | |
| 650 | 4 | |a Gonadotropin-releasing hormone-Agonist | |
| 650 | 4 | |a Gonadotropin-releasing hormone-Antagonist | |
| 650 | 4 | |a Prostate neoplasms | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Androgens |2 NLM | |
| 650 | 7 | |a Gonadotropin-Releasing Hormone |2 NLM | |
| 650 | 7 | |a 33515-09-2 |2 NLM | |
| 700 | 1 | |a von Deimling, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Fisch, Margit |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Gero |e verfasserin |4 aut | |
| 700 | 1 | |a Tilki, Derya |e verfasserin |4 aut | |
| 700 | 1 | |a Steuber, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a von Amsberg, Gunhild |e verfasserin |4 aut | |
| 700 | 1 | |a Hengstenberg, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Shariat, Shahrokh F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologie (Heidelberg, Germany) |d 2022 |g 63(2024), 3 vom: 27. März, Seite 262-268 |w (DE-627)NLM332860612 |x 2731-7072 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:262-268 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00120-023-02222-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e 3 |b 27 |c 03 |h 262-268 | ||